ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
MHR Was Associated with Hyperuricemia Risk in Patients with Type 2 Diabetes Mellitus: The Mediating Effect of Body Mass Index.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence and risk factors of hyperuricemia and gout in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Sex-Specific Associations of Monocyte-Based Inflammatory Indices with Renal Dysfunction and Hyperuricemia in the Saudi General Adult Population.Healthcare (Basel, Switzerland) · 2026Article
- Immune cells and high-density lipoprotein cholesterol derivative markers mediate the impact of hypertriglyceridemia on hyperuricemia in diabetes mellitus.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The monocyte-to-high-density lipoprotein cholesterol ratio (MHR) reflects systemic inflammation, combining the pro-inflammatory role of monocytes with the anti-atherogenic and anti-inflammatory properties of HDL-cholesterol. Prior studies have established MHR as an independent predictor of hyperuricemia (HUA) prevalence. Emerging evidence further identifies MHR as a potential biomarker for early type 2 diabetes mellitus (T2DM) screening, likely mediated through its association with insulin resistance. Therefore, our study specifically investigates the relationship between MHR and HUA in a T2DM population. Methods: This cross-sectional study enrolled 1,261 T2DM patients. Logistic regression assessed associations between MHR and HUA. Mediation analysis evaluated body mass index (BMI) as a mediator. Restricted cubic spline (RCS) analysis examined nonlinear relationships. Receiver operating characteristic (ROC) curves compared predictive performance. Results: Elevated MHR (adjusted OR = 2.040, 95% CI: 1.023 to 4.071, p < 0.05) was independently associated with HUA risk. BMI mediated 18.59% of the associations for MHR, respectively. RCS analysis revealed nonlinear patterns, with HUA risk increasing notably when MHR > 0.47. In ROC analysis, MHR demonstrated significant predictive ability for HUA, with an area under the curve (AUC) of 0.62. Conclusion: Higher MHR was significantly associated with HUA risk in T2DM patients, with BMI serving as a key mediator. These markers may aid in early identification of patients at risk and underscore the importance of weight and inflammation control in HUA prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.